{"id":"W2016582872","doi":"10.1186/ar4666","title":"Eculizumab in recalcitrant antiphospholipid antibody syndrome","year":2014,"lang":"en","type":"article","venue":"Arthritis Research & Therapy","topic":"Blood disorders and treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; National Institutes of Health; Lupus Research Alliance; Canadian Arthritis Network; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Arthritis Society; Central New York Community Foundation; Merck KGaA; Lupus Foundation of America","keywords":"Eculizumab; Medicine; Rheumatology; Antiphospholipid syndrome; Internal medicine; Antibody; Hematology; Immunology; Complement system","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006134614,0.0001509723,0.000195877,0.0001128736,0.0001319288,0.00005332566,0.0002482113,0.0001379789,0.00008244366],"category_scores_gemma":[0.00005728756,0.0001388961,0.00008420635,0.0002568097,0.0001623489,0.000007644654,0.00007002839,0.0001910162,0.0000885741],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001248644,"about_ca_system_score_gemma":0.00006396132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003123458,"about_ca_topic_score_gemma":0.0002703306,"domain_scores_codex":[0.9981691,0.0002942631,0.0001941464,0.0004556539,0.000309724,0.0005771752],"domain_scores_gemma":[0.999295,0.00002686492,0.00002427267,0.0004522661,0.00008493231,0.0001166555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005983997,0.001348598,0.04194129,0.00001429636,0.0001464132,0.000234191,0.0001997409,0.00001244823,0.2787727,0.001011817,0.002325445,0.6733947],"study_design_scores_gemma":[0.02166528,0.007854772,0.09036432,0.0002399534,0.000004342909,0.000339652,0.0002284783,0.0001306977,0.2702441,0.005079629,0.6029289,0.0009198545],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859865,0.009500043,0.00008963444,0.0003894437,0.00007559197,0.0003455489,0.00001083921,0.00001320192,0.003589236],"genre_scores_gemma":[0.9740941,0.02491749,0.0001868232,0.0001918957,0.00006508351,0.00006308947,0.0001146133,0.00003149669,0.0003353939],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6724748,"threshold_uncertainty_score":0.5664017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02276751861928777,"score_gpt":0.335105566418028,"score_spread":0.3123380477987402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}